Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Expanded Access Program Protocol for Melphalan Flufenamide in Combination With Dexamethasone in Patients With Triple Class Refractory Multiple Myeloma

NCT04534322 is registered in ClinicalTrials.gov with Oncopeptides AB as lead sponsor.

NCT NCT04534322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04534322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Expanded Access Program Protocol for Melphalan Flufenamide in Combination With Dexamethasone in Patients With Triple Class Refractory Multiple Myeloma
Lead sponsor
Oncopeptides AB
Phase
Expanded access
Overall status
Approved for marketing
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or refractory multiple myeloma